MF Clinical Trials

107 recruitingLast updated: June 18, 2026

There are 107 actively recruiting mf clinical trials across 42 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 4, Phase 3, Early Phase 1. Top locations include New York, New York, United States, Houston, Texas, United States, Tampa, Florida, United States. Updated daily from ClinicalTrials.gov.


MF Trials at a Glance

107 actively recruiting trials for mf are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Not Applicable with 42 trials, with the heaviest enrollment activity in New York, Houston, and Tampa. Lead sponsors running mf studies include The University of Sydney, Brien Holden Vision Institute, and Chengdu Zenitar Biomedical Technology Co., Ltd.

Treatments under study

About MF Clinical Trials

Looking for clinical trials for MF? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MF trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MF clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 107 trials

Recruiting

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

Genetic diseasesFeverROSAH+4 more
National Human Genome Research Institute (NHGRI)5,000 enrolled5 locationsNCT00001373
Recruiting
Phase 3

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled13 locationsNCT07357727
Recruiting
Phase 1

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Novartis Pharmaceuticals6 enrolled7 locationsNCT07340138
Recruiting
Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

SarcomaNon-small Cell Lung CancerNSCLC+12 more
Epkin146 enrolled10 locationsNCT06789172
Recruiting
Not Applicable

Refitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact Lenses

PresbyopiaContact Lens Comfort and Successful Refitting
Gordon Schanzlin New Vision30 enrolled1 locationNCT07638943
Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Primary myelofibrosis (PMF)Post-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Prelude Therapeutics100 enrolled5 locationsNCT07469891
Recruiting
Not Applicable

J-Tip Use for Paracentesis in Adults With Ascites

Evaluate Patient Comfort Level During Paracentesis by Numbing Skin With a Needle-less Device, Instead of Using a Needle to Numb the Skin
Northwestern University110 enrolled1 locationNCT06996379
Recruiting
Not Applicable

Effect of Yoga and Values Clarification on Stress, Comfort, and Emotional Regulation in Parents of Children With Special Needs

StressEmotional RegulationComfort
Ankara Yildirim Beyazıt University66 enrolled1 locationNCT07628569
Recruiting
Not Applicable

Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP

Prostate Cancer (Post Prostatectomy)Perioperative AnestheticCatheter-related Bladder Discomfort (CRBD)
Zhejiang University130 enrolled1 locationNCT07607990
Recruiting
Not Applicable

Compliance With PROMs Detection Through Digital Support and Correlation Compared Standard to Outpatient Detection in Knee Prosthetics

Knee DiscomfortApproach-Approach Conflict
Istituto Ortopedico Rizzoli50 enrolled1 locationNCT04752761
Recruiting

Ilaris NIS in Korea

Systemic Juvenile Idiopathic Arthritis (sJIA)Hereditary Periodic Fever SyndromesCryopyrin-associated Periodic Syndromes (CAPS)+3 more
Novartis Pharmaceuticals25 enrolled1 locationNCT06838143
Recruiting
Not Applicable

Comparison of Patient-reported Pain After Initial Archwire Placement

Pain, OrofacialOrthodontic Discomfort
University of Colorado, Denver126 enrolled1 locationNCT03906422
Recruiting
Phase 2

A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis

MF
Chengdu Zenitar Biomedical Technology Co., Ltd64 enrolled2 locationsNCT07443306
Recruiting
Not Applicable

NT-II™ Collagen for Joint Discomfort and Function

Joint DiscomfortActivity-Related Knee DiscomfortFunctional Joint Pain+2 more
Hofseth Biocare ASA120 enrolled1 locationNCT07119645
Recruiting
Not Applicable

Comfort Intervention in PICU Children

Anxiety in childrenSleepFear+2 more
Ankara Yildirim Beyazıt University86 enrolled1 locationNCT07441668
Recruiting
Phase 1

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Ajax Therapeutics, Inc.76 enrolled21 locationsNCT06343805
Recruiting

Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

Primary myelofibrosis (PMF)Essential Thrombocythemia, ETMyeloproliferative Neoplasm (MPN)+1 more
Université Catholique de Louvain150 enrolled1 locationNCT07590986
Recruiting
Phase 2

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Icahn School of Medicine at Mount Sinai10 enrolled9 locationsNCT05835466
Recruiting
Early Phase 1

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis (MF)
University of Kansas Medical Center20 enrolled1 locationNCT06414681
Recruiting
Not Applicable

Evaluation of the Synergistic Effect of Combining a Prebiotic and a Postbiotic on Intestinal Discomfort

Intestinal DiscomfortAbdominal Pain/ Discomfort
Université Catholique de Louvain140 enrolled1 locationNCT07420231